| Autor: |
Høgdal, Estrid, Schnack, Tine, Dahl Steffensen, Karina, Jochumsen, Kirsten, Kahr, Henriette Strøm, Hjorth Ingerslev, Kasper, Antonsen, Sofie Leisby, Christensen, IJ, Høgdall, Claus Kim |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Zdroj: |
Høgdal, E, Schnack, T, Dahl Steffensen, K, Jochumsen, K, Kahr, H S, Hjorth Ingerslev, K, Antonsen, S L, Christensen, IJ & Høgdall, C K 2020, ' National coverage of biological materials for translational research in the Danish cancerbiobank (RBGB) and of corresponding clinical data in the Danish Gynecological Cancer Database (DGCD) : 645-Poster Session ', SGO Annual Meeting of Women's Cancer, Toronto, Canada, 28/03/2020-31/03/2020 . < https://www.sgo.org/wp-content/uploads/2020/03/SGO-2020-Annual-Meeting-Posters.pdf > |
| Popis: |
Objective: Optimal personalized medicine may be based on specific predictive/prognostic biomarkers in order to discern between responders and nonresponders. Knowledge of markers is based on biomarker studies analyzing clinical data and their associated biological materials stored in high-quality biobanks. There is no precise knowledge of the extent of nationwide clinical data and corresponding biological specimens available for translational research in gynecologic cancer diseases in Denmark. The aim was to investigate the coverage of biological materials in the Bio- and GenomeBank, Denmark (RBGB), for patients with primary ovarian cancer (tubal, peritoneal, and ovarian) registered in the nationwide compulsory Danish Gynecological Cancer Database (DGCD) for the period 2015–2018.Method: The study is based on data from DGCD and RBGB. Descriptive statistics are used (SAS v9.4).Results: A total of 2,182 women with a primary ovarian cancer diagnosis during the period are registered in DGCD. RBGB contains biological material from 322 (70%, 2018), 399 (70%, 2017), 403 (70%, 2016), and 323 (56%, 2015) of the patients. Blood samples are available for 1,069 patients (49%), and tissue samples are available for 821 patients (38%). Overall, corresponding blood and tissue exist for 443 patients (20%). The coverage ratio on biological material was 66%. Detailed analyses show promising possibilities to combine and correlate DGCD data with more detailed biobank specimens including corresponding data about the material.Conclusion: Biological materials stored in RBGB are clinically useable for both the patient's current and future established treatments. The link between RBGB and DGCD establishes a very promising basis for future translational research in newer individualized treatments. With the strategy for personalized medicine, it is important to continuously ensure optimal biological materials, thereby forming the basis for both the patient's personalized treatment and future research. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
